NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/20/2024
Back to search
Official data from USPTO
CARISMA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
CARISMA THERAPEUTICS
ST13
US500000090179264Class
5
Filing
90179264
Registration
7482488
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
55
Latest update
08/20/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
09/14/2020
Registration date
08/20/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/20/2024
Last transaction
08/20/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/03/2023
First use in commerce
01/03/2023
Drawing code
4
Owner type
03
Owner location
Philadelphia, PA, US
Examiner
OAKES, JEFFREY
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Carisma Therapeutics Inc.
Representatives
Sara M. Bauer Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations, namely, preparations for use in the treatment of cancer and tumors; biologic preparations for medical and therapeutic purposes for immunotherapy; biological preparations for immunotherapy, including, macrophage platforms and T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use
Publications
History of USPTO decisions and trademark events.
55 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/20/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/16/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/16/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/14/2024
GNRT
NON-FINAL ACTION E-MAILED
07/14/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
07/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/21/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/21/2024
ALIE
ASSIGNED TO LIE
06/21/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/26/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/02/2024
GNRT
NON-FINAL ACTION E-MAILED
02/02/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
02/02/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/23/2024
IUAF
USE AMENDMENT FILED
01/23/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/23/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/25/2023
EX5G
SOU EXTENSION 5 GRANTED
10/24/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/23/2023
EXT5
SOU EXTENSION 5 FILED
10/11/2023
EEXT
SOU TEAS EXTENSION RECEIVED
10/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/05/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/05/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/05/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/05/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/29/2023
EX4G
SOU EXTENSION 4 GRANTED
03/27/2023
EXT4
SOU EXTENSION 4 FILED
03/27/2023
EEXT
SOU TEAS EXTENSION RECEIVED
03/27/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/30/2022
EX3G
SOU EXTENSION 3 GRANTED
09/28/2022
EXT3
SOU EXTENSION 3 FILED
09/28/2022
EEXT
SOU TEAS EXTENSION RECEIVED
09/28/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/30/2022
EX2G
SOU EXTENSION 2 GRANTED
03/28/2022
EXT2
SOU EXTENSION 2 FILED
03/28/2022
EEXT
SOU TEAS EXTENSION RECEIVED
03/28/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/31/2021
EX1G
SOU EXTENSION 1 GRANTED
08/27/2021
EXT1
SOU EXTENSION 1 FILED
08/27/2021
EEXT
SOU TEAS EXTENSION RECEIVED
08/27/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/27/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/02/2021
PUBO
PUBLISHED FOR OPPOSITION
03/02/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/27/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
01/27/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/27/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
01/27/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/27/2021
DOCK
ASSIGNED TO EXAMINER
01/26/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/22/2020
NWAP
NEW APPLICATION ENTERED
09/17/2020
Continuous trademark protection
Get notified about every new filing that threatens CARISMA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.